Trial Profile
A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary) ; Antiepileptic drugs
- Indications Complex partial epilepsy
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 05 Feb 2013 Primary endpoint amended as reported by ClinicalTrials.gov record.
- 13 Mar 2012 New trial record